Resistance of cetuximab was reversed in CRC from administering cetuximab-conjugated gold NPs, which increased EGFR endocytosis and degradation, leading to suppression of downstream signaling pathways and decreased tumor growth (174). The gene discussed is EGFR; the disease is colorectal carcinoma.